Display options
Cite
Mellor-Crummey LE, Lake JE, Wilhalme H, et al. A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus. J Clin Gastroenterol Hepatol. 2018;2(3)doi: 10.21767/2575-7733.1000045.
Mellor-Crummey, L. E., Lake, J. E., Wilhalme, H., Tseng, C. H., Grant, P. M., Erlandson, K. M., Price, J. C., Palella, F. J., Kingsley, L. A., Budoff, M., Post, W. S., & Brown, T. T. (2018). A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus. Journal of clinical gastroenterology and hepatology, 2(3), . https://doi.org/10.21767/2575-7733.1000045
Mellor-Crummey, Lauren E, et al. "A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus." Journal of clinical gastroenterology and hepatology vol. 2,3 (2018). doi: https://doi.org/10.21767/2575-7733.1000045
Mellor-Crummey LE, Lake JE, Wilhalme H, Tseng CH, Grant PM, Erlandson KM, Price JC, Palella FJ, Kingsley LA, Budoff M, Post WS, Brown TT. A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus. J Clin Gastroenterol Hepatol. 2018;2(3). doi: 10.21767/2575-7733.1000045. Epub 2018 Jul 30. PMID: 30511049; PMCID: PMC6269145.
Copy Download .nbib Format: NLM
Share it on

J Clin Gastroenterol Hepatol. 2018;2(3). doi: 10.21767/2575-7733.1000045. Epub 2018 Jul 30.

A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus.

Journal of clinical gastroenterology and hepatology

Lauren E Mellor-Crummey, Jordan E Lake, Holly Wilhalme, Chi-Hong Tseng, Philip M Grant, Kristine M Erlandson, Jennifer C Price, Frank J Palella, Larry A Kingsley, Matthew Budoff, Wendy S Post, Todd T Brown

Affiliations

  1. McGovern Medical School at the UT Health Science Center at Houston, Houston, TX, USA.
  2. University of California Los Angeles, Los Angeles, CA, USA.
  3. Stanford University, Stanford, CA, USA.
  4. University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  5. University of California San Francisco, San Francisco, CA, USA.
  6. Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  7. University of Pittsburgh, Pittsburgh, PA, USA.
  8. Los Angeles Biomedical Research Institute, Torrance, CA, USA.
  9. Johns Hopkins University, Baltimore, MD, USA.

PMID: 30511049 PMCID: PMC6269145 DOI: 10.21767/2575-7733.1000045

Abstract

BACKGROUND AND AIM: Non-alcoholic fatty liver disease (NAFLD) is common among HIV-infected (HIV+) adults. The Liver Fat Score (LFS) is a non-invasive, rapid, inexpensive diagnostic tool that uses routine clinical data and is validated against biopsy in HIV-uninfected (HIV-) persons. CT liver-to-spleen (L/S) attenuation ratio is another validated method to diagnose NAFLD. We compared NAFLD prevalence using the LFS versus L/S ratio among Multicenter AIDS Cohort Study participants to assess the LFS's performance in HIV+vs. HIV-men.

METHODS: In a cross-sectional analysis of men reporting<3 alcoholic drinks daily (308 HIV+, 218 HIV-), Spearman correlations determined relationships between LFS and L/S ratio by HIV serostatus. Multivariable regression determined factors associated with discordance in LFS- and L/S ratio-defined NAFLD prevalence.

RESULTS: NAFLD prevalence by LFS and L/S ratio were 28%/15% for HIV+men and 20%/19% for HIV-men, respectively. Correlations between LFS and L/S ratio were weaker among HIV+than HIV-men, but improved with increasing BMI and exclusion of HCV-infected men. LFS and L/S ratio discordance occurred more frequently and across BMI strata among HIV+men, but predominantly at BMI<30 kg/m

CONCLUSION: NAFLD prevalence was similar by LFS and L/S ratio identification among HIV-men, but dissimilar and with frequent discordance between the two tests among HIV+men. As discordance may be multifactorial, biopsy data are needed to determine the best non-invasive diagnostic test for NAFLD in HIV+persons.

Keywords: Hepatic steatosis; Human immunodeficiency; Non-alcoholic steatohepatitis

References

  1. Minerva Endocrinol. 2017 Jun;42(2):145-150 - PubMed
  2. South Med J. 2008 Sep;101(9):900-5 - PubMed
  3. BMC Med. 2014 Sep 10;12:154 - PubMed
  4. AIDS. 1998 May 7;12(7):F51-8 - PubMed
  5. AIDS. 2017 Jan 28;31(3):365-373 - PubMed
  6. Eur Radiol. 2011 Jan;21(1):87-97 - PubMed
  7. AIDS. 1999 Jul 9;13(10):F63-70 - PubMed
  8. Am J Gastroenterol. 2014 May;109(5):695-704 - PubMed
  9. Circulation. 2004 Jan 27;109(3):433-8 - PubMed
  10. J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):173-80 - PubMed
  11. Diabetes Care. 2008 Jun;31(6):1224-9 - PubMed
  12. N Engl J Med. 2002 Apr 18;346(16):1221-31 - PubMed
  13. Am J Epidemiol. 1987 Aug;126(2):310-8 - PubMed
  14. Circulation. 2005 Oct 25;112(17):2735-52 - PubMed
  15. Clin Infect Dis. 2008 Jul 15;47(2):250-7 - PubMed
  16. J Infect Dis. 2017 Jan 15;215(2):228-237 - PubMed
  17. Aliment Pharmacol Ther. 2014 Nov;40(10):1209-22 - PubMed
  18. J Clin Gastroenterol. 2013 Feb;47(2):182-7 - PubMed
  19. Diabetes Metab. 1999 Sep;25(3):225-32 - PubMed
  20. J Gastroenterol Hepatol. 2013 Aug;28(8):1375-83 - PubMed
  21. AIDS. 2017 Jul 17;31(11):1621-1632 - PubMed
  22. Clin Gastroenterol Hepatol. 2015 Feb;13(2):402-5 - PubMed
  23. J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):464-73 - PubMed
  24. Radiology. 2011 Mar;258(3):760-6 - PubMed
  25. PLoS One. 2014 Jan 31;9(1):e87596 - PubMed

Publication Types

Grant support